| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 91,598 | 59,285 | ||
| Trade accounts receivable, net | 53,751 | 53,048 | ||
| Inventory, net | 67,462 | 67,282 | ||
| Prepaid expenses and other current assets | 11,206 | 5,963 | ||
| Total current assets | 224,017 | 185,578 | ||
| Property and equipment, net | 4,946 | 5,284 | ||
| Operating lease right-of-use assets | 22,263 | 22,403 | ||
| Goodwill | 22,859 | 22,859 | ||
| Other assets | 90,789 | 93,500 | ||
| Other assets | 5,317 | 5,062 | ||
| Total assets | 370,191 | 334,686 | ||
| Accounts payable | 6,527 | 9,462 | ||
| Current portion of long-term debt | 0 | 0 | ||
| Current operating lease liabilities | 6,194 | 6,156 | ||
| Other accrued liabilities | 30,350 | 24,969 | ||
| Accrued trade discounts and rebates | 51,264 | 33,169 | ||
| Accrued returns reserve | 19,216 | 19,782 | ||
| Other current liabilities | 2,649 | 1,633 | ||
| Total current liabilities | 116,200 | 95,171 | ||
| Debt, net of unamortized debt issuance costs, non-current portion | 219,469 | 218,626 | ||
| Non-current operating lease liabilities | 31,991 | 32,441 | ||
| Other liabilities | 3,392 | 7,752 | ||
| Total liabilities | 371,052 | 353,990 | ||
| Common stockpar value 0.0001, 350,000,000 shares and 350,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 165,528,253 and 149,429,410 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 17 | 16 | ||
| Additional paid in capital | 681,535 | 663,713 | ||
| Accumulated deficit | -682,388 | -683,009 | ||
| Accumulated other comprehensive loss | -25 | -24 | ||
| Total stockholders' equity (deficit) | -861 | -19,304 | ||
| Total liabilities and stockholders' equity (deficit) | 370,191 | 334,686 | ||
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)